Quantum Biopharma Ltd. (QNTM) stock
QNTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.59+0.15 (+10.42%)
Close on Nov 17, 2026Market cap $6.18MP/E –Yield –
Quantum Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Quantum Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.58M, down 78.1% year over year. For fiscal 2025 it was $2.76M, down 54.6% from the year before. The highest annual figure on record is $7.83M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.76M | -54.6% |
| FY2024 | Dec 31, 2024 | $6.08M | +57.6% |
| FY2023 | Dec 31, 2023 | $3.86M | -44.2% |
| FY2022 | Dec 31, 2022 | $6.91M | +9.2% |
| FY2021 | Dec 31, 2021 | $6.33M | -19.2% |
| FY2020 | Dec 31, 2020 | $7.83M | – |
| FY2019 | Dec 31, 2019 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $387.43K | -29.5% |
| Q1 FY2026 | Mar 31, 2026 | $626.09K | -62.0% |
| Q4 FY2025 | Dec 31, 2025 | $70.40K | -98.4% |
| Q3 FY2025 | Sep 30, 2025 | $495.22K | -33.5% |
| Q2 FY2025 | Jun 30, 2025 | $549.20K | -38.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.65M | +928.5% |
| Q4 FY2024 | Dec 31, 2024 | $4.28M | +12876.6% |
| Q3 FY2024 | Sep 30, 2024 | $744.80K | -53.8% |
| Q2 FY2024 | Jun 30, 2024 | $897.99K | – |
| Q1 FY2024 | Mar 31, 2024 | $160.26K | – |
| Q3 FY2023 | Sep 30, 2023 | $32.99K | – |
| Q2 FY2023 | Jun 30, 2023 | $1.61M | – |
See a number that looks wrong?